DRAK2 participates in a negative feedback loop to control TGF-β/Smads signaling by binding to type I TGF-β receptor

Kyung-Min Yang1, Wonjoo Kim, Eunjin Bae

  • 1CHA Cancer Institute, CHA University of Medicine and Science, Seoul 135-081, Korea.

Cell Reports
|November 6, 2012
PubMed

Insights

Transforming growth factor-beta 1 (TGF-β1) signaling is regulated by DRAK2, a novel antagonist. Aberrant DRAK2 expression in breast cancer promotes tumorigenesis by inhibiting TGF-β1

Area of Science:

  • Cellular Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Transforming growth factor-beta 1 (TGF-β1) is a key cytokine regulating numerous biological processes.
  • The termination mechanisms of intracellular TGF-β1 signaling remain incompletely understood.
  • Understanding these mechanisms is crucial for deciphering cellular regulation and disease pathogenesis.

Purpose of the Study:

  • To identify novel regulators of TGF-β1 signaling termination.
  • To investigate the role of DRAK2 in TGF-β1 pathway regulation.
  • To explore the implications of DRAK2 in breast cancer development and progression.

Main Methods:

  • Investigated TGF-β1-induced gene expression changes.
  • Utilized co-immunoprecipitation to study protein interactions.
  • Employed siRNA to deplete DRAK2 expression in cell lines.
  • Assessed the impact of DRAK2 on TGF-β1 signaling and breast cancer cell tumorigenicity.

Main Results:

  • TGF-β1 stimulation rapidly upregulates DRAK2 expression.
  • DRAK2 interacts with the TGF-β type I receptor, inhibiting R-Smad recruitment.
  • DRAK2 depletion potentiates TGF-β1 signaling.
  • Elevated DRAK2 expression correlates with basal-like and HER2-enriched breast tumors.
  • DRAK2 depletion reduces breast cancer cell tumorigenic potential.

Conclusions:

  • DRAK2 functions as an intrinsic intracellular antagonist in the TGF-β1 signaling negative feedback loop.
  • Aberrant DRAK2 expression contributes to tumorigenesis by potentially inhibiting TGF-β1's tumor suppressor functions.
  • DRAK2 represents a potential therapeutic target in specific breast cancer subtypes.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Cell Signaling Feedback Loops01:07

Cell Signaling Feedback Loops

Positive and negative feedback loops are crucial for regulating biological signaling systems. These feedback loops are processes that connect output signals to their inputs.
Negative feedback loops
Most signaling systems have negative feedback loops that can perform different functions such as output limiter, and adaptation.
Output limiter
Upon receiving an input signal, the cellular response rapidly increases until a threshold is reached. Beyond this threshold, a negative feedback loop...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...